[{"address1": "75 State Street", "address2": "Suite 100", "city": "Boston", "state": "MA", "zip": "02109", "country": "United States", "phone": "617 229 6499", "website": "https://www.finchtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. James S. Sigler MBA", "age": 62, "title": "Executive Vice President of CMC", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.49, "open": 2.55, "dayLow": 2.24, "dayHigh": 2.65, "regularMarketPreviousClose": 2.49, "regularMarketOpen": 2.55, "regularMarketDayLow": 2.24, "regularMarketDayHigh": 2.65, "beta": 0.46, "forwardPE": -0.11170471, "volume": 53317, "regularMarketVolume": 53317, "averageVolume": 47069, "averageVolume10days": 106250, "averageDailyVolume10Day": 106250, "marketCap": 3693248, "fiftyTwoWeekLow": 1.86, "fiftyTwoWeekHigh": 16.74, "priceToSalesTrailing12Months": 34.51634, "fiftyDayAverage": 2.51122, "twoHundredDayAverage": 4.14485, "currency": "USD", "enterpriseValue": 8695255, "floatShares": 792862, "sharesOutstanding": 1605760, "sharesShort": 10600, "sharesShortPriorMonth": 11631, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0066000004, "heldPercentInsiders": 0.53481, "heldPercentInstitutions": 0.15017, "shortRatio": 0.87, "shortPercentOfFloat": 0.0117, "impliedSharesOutstanding": 1605760, "bookValue": 14.252, "priceToBook": 0.16138086, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -74754000, "trailingEps": -46.59, "forwardEps": -20.59, "lastSplitFactor": "1:30", "lastSplitDate": 1686528000, "enterpriseToRevenue": 81.264, "enterpriseToEbitda": -0.268, "52WeekChange": -0.7898734, "SandP52WeekChange": 0.22379243, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FNCH", "underlyingSymbol": "FNCH", "shortName": "Finch Therapeutics Group, Inc.", "longName": "Finch Therapeutics Group, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b8e86349-7dce-3756-a76c-43df24d3f738", "messageBoardId": "finmb_320858778", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.3, "targetHighPrice": 90.0, "targetLowPrice": 90.0, "targetMeanPrice": 90.0, "targetMedianPrice": 90.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 25124000, "totalCashPerShare": 15.646, "ebitda": -32482000, "totalDebt": 30126000, "quickRatio": 6.152, "currentRatio": 6.329, "totalRevenue": 107000, "debtToEquity": 131.635, "revenuePerShare": 0.067, "returnOnAssets": -0.19469, "returnOnEquity": -1.26064, "freeCashflow": -23909250, "operatingCashflow": -31505000, "revenueGrowth": -1.0, "operatingMargins": -317.7757, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]